Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 21;7(13):e008259. doi: 10.1161/JAHA.117.008259

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Changes in urinary sodium excretion and blood pressure under DOC+SPL treatment. Gray lines indicate the changes under DOCA/salt treatment, as shown in Figure 3C and 3I. Black lines indicate the changes under DOC+SPL treatment. Urinary sodium excretion (A and B) and systolic blood pressure (D and E) in control and IEC‐MR‐KO mice. C, Urinary sodium excretion in all groups at 12 weeks of age. F, Blood pressure in all groups at 13 weeks of age. Arrows indicate the start of spironolactone treatment. Data are presented as mean±SEM. P<0.05 vs *control (Cont), ^# DOCA/salt. DOC+SPL indicates deoxycorticosterone acetate/salt treatment plus spironolactone; DOCA, deoxycorticosterone acetate; IEC‐MR‐KO, intestinal epithelial cell–specific mineralocorticoid receptor knockout.